All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

vinpocetine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2828	42971-09-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cavinton ethyl apovincaminate tartrate vinpocetine apovincaminic acid ethyl ester bravinton ceractin ethyl apovincaminate vinporal	whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation Molecular weight: 350.46 Formula: C22H26N2O2 CLOGP: 4.83 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 34.47 ALOGS: -4.14 ROTB: 4

Drug dosage:

Dose	Unit	Route
15	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	33 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.08 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	6.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.83 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	50
kinase-selectivity-class	AXL,BRAF,GRK2	3
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tension	109.82	50.47	20	738	3662	90624027
Disturbance in attention	63.17	50.47	21	737	47088	90580601
Cognitive disorder	62.54	50.47	23	735	69384	90558305
Psychomotor retardation	62.32	50.47	13	745	4776	90622913
Flat affect	62.19	50.47	11	747	1700	90625989
Bradykinesia	57.81	50.47	13	745	6775	90620914
Illusion	51.79	50.47	9	749	1255	90626434
Autism spectrum disorder	51.58	50.47	9	749	1284	90626405
Anhedonia	51.07	50.47	13	745	11418	90616271

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tension	102.94	40.19	20	924	5058	110583297
Flat affect	57.76	40.19	11	933	2494	110585861
Disturbance in attention	57.05	40.19	21	923	61974	110526381
Cognitive disorder	56.84	40.19	23	921	87488	110500867
Psychomotor retardation	55.73	40.19	13	931	7779	110580576
Bradykinesia	51.53	40.19	13	931	10775	110577580
Autism spectrum disorder	47.70	40.19	9	935	1939	110586416
Illusion	47.44	40.19	9	935	1998	110586357
Overweight	47.37	40.19	11	933	6453	110581902
Anhedonia	46.92	40.19	13	931	15415	110572940

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BX18	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Other psychostimulants and nootropics
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D018697	Nootropic Agents
MeSH PA	D020011	Protective Agents
CHEBI has role	CHEBI:176497	geroprotector

Related Drugs by ATC class:

N06BX Other psychostimulants and nootropics 19 drugs

acetylcarnitineadrafinilaniracetamcinnarizineciticolinedeanolfipexideidebenonelinopirdinemeclofenoxatenizofenoneoxiracetam show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dementia	indication	52448006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	7.41		CHEMBL
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Enzyme	P54750	PDE1A_HUMAN		IC50	5.10		CHEMBL
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Enzyme	Q14123	PDE1C_HUMAN	INHIBITOR	IC50	4.30		IUPHAR
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Enzyme	Q01064	PDE1B_HUMAN		IC50	5.10		CHEMBL
Phosphodiesterase 1	Enzyme		PDE1A_BOVIN PDE1B_BOVIN		IC50	4.72		CHEMBL

External reference:

ID	Source
4024909	VUID
N0000171574	NUI
D01371	KEGG_DRUG
4024909	VANDF
C0059752	UMLSCUI
CHEBI:32297	CHEBI
T7F	PDB_CHEM_ID
CHEMBL71752	ChEMBL_ID
DB12131	DRUGBANK_ID
C013983	MESH_SUPPLEMENTAL_RECORD_UI
443955	PUBCHEM_CID
5285	IUPHAR_LIGAND_ID
4046	INN_ID
543512OBTC	UNII
24506	RXNORM
005991	NDDF
716059001	SNOMEDCT_US

Pharmaceutical products:

None